Cardiac Troponin Diagnostics—Forecasts and Opportunities to 2025

Healthcare Cardiac Troponin Diagnostics—Forecasts and Opportunities to 2025

Demand for High Sensitivity Point-of-Care Testing Enhance Growth Potential

INDUSTRY
Healthcare

RELEASE DATE
16-Nov-2022
REGION
North America
DELIVERABLE TYPE
Market Research

RESEARCH CODE
PDB7-01-00-00-00
SKU
HC03602-NA-MT_27122
Yes
SHARE

$4,950.00

Special Price $3,712.50 save 25 %

In stock
SKU
HC03602-NA-MT_27122

Cardiac Troponin Diagnostics—Forecasts and Opportunities to 2025
Published on: 16-Nov-2022 | SKU: HC03602-NA-MT_27122

Need more details?

$4,950.00

$3,712.50 save 25 %

DownloadLink
Need more details?

Cardiac troponin (cTn) biomarkers are the gold standard in myocardial infarction (MI) diagnosis, leading healthcare professionals to use cTn diagnostics. In addition, a rising number of patients visit emergency departments (EDs) with cardiac complaints, increasing ED demand for kits
that can rapidly rule MI in or out. Both factors serve as significant drivers of the cTn diagnostics market.

Hospitals and clinical laboratories adopt high-sensitivity (hs) assays because of their ability to detect troponin in lower concentrations. The point-of-care testing (POCT) of cTn grows rapidly due to its rising applications in EDs and remote locations. POCT can provide rapid results in a shorter period than lab-based tests. In addition, companies such as QuidelOrtho and Siemens Healthineers have developed high-sensitivity POCT cTn assays that provide accurate results within a few minutes.

In this report, Frost & Sullivan overviews the cTn diagnostics market and includes troponin I and troponin T. Our testing locations are independent laboratories, physicians’ offices, urgent care and nursing facilities, inpatient hospitals, and emergency rooms. The study covers sensitive and
hs-cTn tests.

The report also includes the following:
• Market size by revenue, covering historic and forecast data by segment (lab-based tests and POCT) and region (North America, Europe,
Asia-Pacific, and the rest of the world)
• Challenges and drivers
• Competitive landscape, including company market share for lab-based tests and POCT
• Future trends and growth opportunities for stakeholders

North America is the leading region in the cTn diagnostics market, with hospitals and laboratories shifting toward high-sensitivity assays following approval from the United States Food and Drug Administration in 2017. Frost & Sullivan’s research shows high consolidation in the cTn diagnostics market, with players such as Abbot, Roche, and Siemens Healthineers dominating. New players are entering this market, especially in the POCT segment.

Why is it Increasingly Difficult to Grow?

The Strategic Imperative 8™

The Impact of the Top 3 Strategic Imperatives on the Cardiac Troponin (cTn) Diagnostics Industry

Growth Opportunities Fuel the Growth Pipeline Engine™

Cardiac Biomarkers

Timeline for Cardiac Biomarkers for MI

cTns

Clinical Pathway for MI Diagnosis

cTn Diagnostics

cTn Diagnostics (continued)

Scope of Analysis

Segmentation

Competitors

Growth Metrics

Growth Drivers

Growth Restraints

Forecast Assumptions

Revenue Forecast

Revenue Forecast by Product Type

Revenue Forecast by Region

Revenue Forecast Analysis

Revenue Forecast Analysis (continued)

Revenue Forecast Analysis by Region

Competitive Environment

Revenue Share

Revenue Share Analysis

Company Mapping

Companies to Watch

High-sensitivity Troponin Diagnostic—Emerging Applications

New Biomarkers for MI

Growth Metrics

Revenue Forecast

Revenue Forecast by Region

Forecast Analysis

Growth Metrics

Revenue Forecast by Product Type

Revenue Forecast by Region

Forecast Analysis

Growth Opportunity 1: Rapid Diagnostics for EDs

Growth Opportunity 1: Rapid Diagnostics for EDs (continued)

Growth Opportunity 2: hs-cTn POCT

Growth Opportunity 2: hs-cTn POCT (continued)

Growth Opportunity 3: Digital Health and Diagnostics Inter-convergence Model

Growth Opportunity 3: Digital Health and Diagnostics Inter-convergence Model (continued)

Growth Opportunity 4: Specific and Sensitive Assays for Rapid MI Detection

Growth Opportunity 4: Specific and Sensitive Assays for Rapid MI Detection (continued)

Your Next Steps

Why Frost, Why Now?

List of Exhibits

Legal Disclaimer

List of Figures
  • cTn Diagnostics: Growth Metrics, Global, 2021
  • cTn Diagnostics: Growth Drivers, Global, 2022–2025
  • cTn Diagnostics: Growth Restraints, Global, 2022–2025
  • cTn Diagnostics: Revenue Forecast, Global, 2017–2025
  • cTn Diagnostics: Revenue Forecast by Product Type, Global, 2017–2025
  • cTn Diagnostics: Revenue Forecast by Region, 2017–2025
  • cTn Diagnostics: Revenue Share of Top Participants, Global, 2021
  • cTn Diagnostics: Product Comparison by Company, 2022
  • Lab-based Tests: Growth Metrics, Global, 2021
  • Lab-based Tests: Revenue Forecast, Global, 2017–2025
  • Lab-based Tests: Revenue Forecast by Region, Global, 2017–2025
  • POCT: Growth Metrics, Global, 2021
  • POCT: Revenue Forecast, Global, 2017–2025
  • POCT: Revenue Forecast by Region, Global, 2017–2025

Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.

Recent related Healthcare research

27 Aug 2026   |   Global   |   Frost Radar

Frost Radar: AI-Powered Molecular Diagnostics, 2026

AI-powered molecular diagnostics is an emerging and moderately fragmented industry that includes molecular diagnostics companies, precision medicine platforms, sequencing specialists, AI-driven analytics providers, and disease-focused biotechnology companies. No single company has dominated, present...

26 Aug 2026   |   Global   |   Technology Research

Growth Opportunities and Advancements in Acute and Chronic Wound Care

A wound is any disruption in the normal structure and function of the skin or underlying tissues. It can result from physical injury, surgery, or underlying medical conditions. Wounds are broadly classified into two categories: acute wounds and chronic wounds. Acute wounds typically heal through the...

26 Aug 2026   |   Global   |   Frost Radar

Frost Radar™: Healthcare Infrastructure Cybersecurity in the United States, 2026

Healthcare organizations are expanding their digital environments across cloud infrastructure, connected medical devices, applications, identities, operational technology, and distributed care settings, creating a broader and increasingly interconnected attack surface. Cybersecurity is, therefore, e...

25 Aug 2026   |   Global   |   Technology Research

Breakthrough Innovations in Point-of-Care Diagnostics

This research analyzes how point-of-care (PoC) diagnostics is evolving from simple tests to decentralized, connected, and clinically actionable testing platforms across hospitals, outpatient settings, homes, and pharmacies.

The study assesses key technology shifts, including rapid molecular t...

25 Aug 2026   |   Global   |   Technology Research

Innovations and Growth Opportunities in Digital Biomarkers

A digital biomarker refers to measurable data about physiological functions or behaviors collected through digital devices and technologies, such as wearables, implants, ingestible sensors, smartphones, and mobile applications.

These biomarkers provide continuous, real-time insights into an ...

 

Purchase includes:
  • Report download
  • Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.

Cardiac troponin (cTn) biomarkers are the gold standard in myocardial infarction (MI) diagnosis, leading healthcare professionals to use cTn diagnostics. In addition, a rising number of patients visit emergency departments (EDs) with cardiac complaints, increasing ED demand for kits that can rapidly rule MI in or out. Both factors serve as significant drivers of the cTn diagnostics market. Hospitals and clinical laboratories adopt high-sensitivity (hs) assays because of their ability to detect troponin in lower concentrations. The point-of-care testing (POCT) of cTn grows rapidly due to its rising applications in EDs and remote locations. POCT can provide rapid results in a shorter period than lab-based tests. In addition, companies such as QuidelOrtho and Siemens Healthineers have developed high-sensitivity POCT cTn assays that provide accurate results within a few minutes. In this report, Frost & Sullivan overviews the cTn diagnostics market and includes troponin I and troponin T. Our testing locations are independent laboratories, physicians’ offices, urgent care and nursing facilities, inpatient hospitals, and emergency rooms. The study covers sensitive and hs-cTn tests. The report also includes the following: • Market size by revenue, covering historic and forecast data by segment (lab-based tests and POCT) and region (North America, Europe, Asia-Pacific, and the rest of the world) • Challenges and drivers • Competitive landscape, including company market share for lab-based tests and POCT • Future trends and growth opportunities for stakeholders North America is the leading region in the cTn diagnostics market, with hospitals and laboratories shifting toward high-sensitivity assays following approval from the United States Food and Drug Administration in 2017. Frost & Sullivan’s research shows high consolidation in the cTn diagnostics market, with players such as Abbot, Roche, and Siemens Healthineers dominating. New players are entering this market, especially in the POCT segment.
More Information
Deliverable Type Market Research
Industries Healthcare
No Index No
Is Prebook No
List of Charts and Figures cTn Diagnostics: Growth Metrics, Global, 2021~ cTn Diagnostics: Growth Drivers, Global, 2022–2025~ cTn Diagnostics: Growth Restraints, Global, 2022–2025~ cTn Diagnostics: Revenue Forecast, Global, 2017–2025~ cTn Diagnostics: Revenue Forecast by Product Type, Global, 2017–2025~ cTn Diagnostics: Revenue Forecast by Region, 2017–2025~ cTn Diagnostics: Revenue Share of Top Participants, Global, 2021~ cTn Diagnostics: Product Comparison by Company, 2022~ Lab-based Tests: Growth Metrics, Global, 2021~ Lab-based Tests: Revenue Forecast, Global, 2017–2025~ Lab-based Tests: Revenue Forecast by Region, Global, 2017–2025~ POCT: Growth Metrics, Global, 2021~ POCT: Revenue Forecast, Global, 2017–2025~ POCT: Revenue Forecast by Region, Global, 2017–2025~
Podcast No
WIP Number PDB7-01-00-00-00